At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 1,096 enrolled
Drug / intervention
Venlafaxine ERdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Acute and Continuation Phase Study of the Comparative Efficacy Study of Venlafaxine ER (Effexor® XR) and Fluoxetine (Prozac®) in Achieving and Sustaining Remission (Wellness) in Patients With Recurrent Unipolar Major Depression; Followed by a Long Term Randomized, Placebo-Controlled Maintenance Treatment Study in Patients Treated Initially With Venlafaxine ER
Wyeth is now a wholly owned subsidiary of Pfizer·interventional·Posted Sep 19, 2002·Updated Aug 14, 2009
In Brief
A Phase 4 clinical trial evaluating Venlafaxine ER for Depressive Disorder, Major and Recurrence. Completed, enrolled 1,096 participants.
Detailed Summary
The purpose of this study is to review the long-term comparative efficacy of venlafaxine ER in achieving and sustaining remission (wellness) in patients with recurrent major depression
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDepressive Disorder, Major, Recurrence
Countries--
Collaborators--
Timeline
Phase 4CompletedFinished
2000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartAug 2000
First PostedSep 2002
Primary CompletionOct 2005
TodayJul 2026
First PostedSep 19, 2002
Enrollment StartAug 1, 2000
Primary CompletionOct 1, 2005
TodayJul 2, 2026
Enrollment to primary: 5.2 yearsPosted 23.8 years ago
Interventions
Venlafaxine ERdrug